Cohesin RAD21 Gene Promoter Methylation Correlated with Better Prognosis in Breast Cancer Patients

Rongrong Cui; Pu Chen; Yuanyuan Wang; Rong Lu; Meiju Ji; Peng Hou; Yiping Qu

doi:10.1159/000524735

Cohesin RAD21 Gene Promoter Methylation Correlated with Better Prognosis in Breast Cancer Patients

Cytogenet Genome Res. 2022;162(3):109-118. doi: 10.1159/000524735. Epub 2022 Jun 2.

Authors

Rongrong Cui¹, Pu Chen¹, Yuanyuan Wang¹, Rong Lu¹, Meiju Ji², Peng Hou¹, Yiping Qu^{1

3}

Affiliations

¹ Key Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
² Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
³ Department of Radio Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

PMID: 35654004
DOI: 10.1159/000524735

Abstract

RAD21 plays multiple roles in numerous cancers. In breast cancer (BC), a high level of RAD21 correlates with poor disease outcomes and resistance to chemotherapy. However, data regarding RAD21 promoter methylation in BC tissue and its correlation with clinical outcomes in patients with BC remain limited. Here, we investigated the clinicopathological features associated with the methylation status of RAD21 in BC to figure out its possible role in pathogenesis and the formation of breast carcinogenesis. The methylation status of the RAD21 gene was significantly associated with better clinical outcomes in patients with BC.

Keywords: Breast cancer; Clinical outcomes; Methylation-specific PCR; Promotor methylation; RAD21.

MeSH terms

Breast Neoplasms* / diagnosis
Breast Neoplasms* / genetics
Cell Cycle Proteins* / genetics
Chromosomal Proteins, Non-Histone
Cohesins
DNA Methylation
DNA-Binding Proteins* / genetics
Female
Humans
Prognosis
Promoter Regions, Genetic

Substances

Cell Cycle Proteins
Chromosomal Proteins, Non-Histone
DNA-Binding Proteins
RAD21 protein, human